Lataa...
“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn
We report a case of carbamazepine withdrawal syndrome following in utero exposure to carbamazepine related to a pharmacogenetic predisposition factor. The infant was born at 37 1/7 weeks’ gestation by cesarean section to a mother treated for epilepsy with carbamazepine. One hour and thirty minutes a...
Tallennettuna:
Julkaisussa: | Front Pharmacol |
---|---|
Päätekijät: | , , , , , |
Aineistotyyppi: | Artigo |
Kieli: | Inglês |
Julkaistu: |
Frontiers Media S.A.
2017
|
Aiheet: | |
Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5399605/ https://ncbi.nlm.nih.gov/pubmed/28484392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00217 |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|